Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1123a in advanced solid tumors
NCT02690337Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2016
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-1123 in solid tumor (advanced stage), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum concentration, Treatment Emergent Adverse Events and 9 more. Started Jan 2016; status: completed.
02
Drugs
DS-1123
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02690337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690337.